Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-alanine is the D-enantiomer of the amino acid alanine, primarily recognized for its essential role in the biosynthesis of bacterial peptidoglycan. Unlike the L-enantiomer used in protein synthesis, D-alanine is incorporated into the bacterial cell wall, where it is cross-linked by enzymes such as D-alanine-D-alanine ligase and penicillin-binding proteins to maintain structural integrity. In human physiology, D-alanine acts as a potent co-agonist at the glycine-binding site of the N-methyl-D-aspartate (NMDA) receptor, which has led to its investigation as a therapeutic agent for neuropsychiatric conditions like schizophrenia. Furthermore, its selective uptake and metabolism by bacteria have enabled its use as a targeting moiety in novel diagnostic probes for the detection of intratumoral bacteria and other infections. It is also available as a dietary supplement and is widely used in research for alanine scanning to determine the importance of specific residues in peptide structure-activity relationship (SAR) studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on d-alanine.